Harrow (HROW) EBT Growth (3y) (2013 - 2026)
Harrow (HROW) EBT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 53.36% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.84% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -64.71% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 2.93% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -40.38% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 63.73% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -6.95% |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | -58.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.46% |
| Dec 31, 2025 | 114.40% |
| Sep 30, 2025 | 29.24% |
| Jun 30, 2025 | 41.04% |
| Mar 31, 2025 | -93.92% |
| Dec 31, 2024 | 41.94% |
| Sep 30, 2024 | 20.40% |
| Jun 30, 2024 | -32.91% |
| Mar 31, 2024 | -301.06% |
| Dec 31, 2023 | -118.68% |
| Sep 30, 2023 | -32.59% |
| Jun 30, 2023 | -153.67% |
| Mar 31, 2023 | 18.75% |
| Dec 31, 2022 | -25.97% |
| Sep 30, 2022 | 17.93% |
| Jun 30, 2022 | -36.83% |
| Mar 31, 2022 | -30.36% |
| Dec 31, 2021 | -33.92% |
| Sep 30, 2021 | -49.07% |
| Jun 30, 2021 | -43.94% |